Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War) Operating Income

As of the most recent data (June 2026), PBAXU shows a operating income of $-17M. That compares with $-29M in the prior-year period — up 38.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PBAXU's operating income is now $-17M (was $-29M) — a 38.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War) is outperforming or lagging.

Tracking PBAXU's operating income over time shows whether Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War) is scaling, shrinking, or reshaping that part of the business. The current reading is $-17M That compares with $-29M in the prior-year period — up 38.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-17M) with ownership activity and broader fundamentals.